IMMUNOTHERAPY

>

Latest News

Novel Oncolytic Therapy Holds Promise for Pretreated Solid Tumors
Novel Oncolytic Therapy Holds Promise for Pretreated Solid Tumors

June 17th 2024

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

Osimertinib Wins FDA Priority Review in Stage III EGFR+ NSCLC
Osimertinib Wins FDA Priority Review in Stage III EGFR+ NSCLC

June 10th 2024

Bridging the Gap Between Oncology and Rheumatology
Bridging the Gap Between Oncology and Rheumatology

June 5th 2024

FDA to Consider Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
FDA to Consider Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

May 7th 2024

Novel CAR T-Cell Therapy Extends PFS in CLL
Novel CAR T-Cell Therapy Extends PFS in CLL

February 17th 2024

Latest CME Events & Activities

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

23rd Annual International Congress on the Future of Breast Cancer® West

July 12-13, 2024

Register Now!

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

View More

Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes

View More

Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure

View More

Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®

View More

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes

View More

22nd Annual School of Breast Oncology

November 7-9, 2024

Register Now!

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer

View More

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs

View More

Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings

View More

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs

View More

School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio

View More

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

Register Now!

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice

View More

More News